| Evaluation of the Andromas matrix-assisted laser desorption ionization–time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli E Farfour, J Leto, M Barritault, C Barberis, J Meyer, B Dauphin, ... Journal of clinical microbiology 50 (8), 2702-2707, 2012 | 133 | 2012 |
| Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 J Lehmann-Che, AS Hamy, R Porcher, M Barritault, F Bouhidel, ... Breast Cancer Research 15, 1-11, 2013 | 122 | 2013 |
| Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study D Campana, T Walter, S Pusceddu, F Gelsomino, E Graillot, N Prinzi, ... Endocrine 60, 490-498, 2018 | 78 | 2018 |
| Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors A Mansuet-Lupo, M Barritault, M Alifano, A Janet-Vendroux, M Zarmaev, ... Journal of Thoracic Oncology 14 (5), 844-856, 2019 | 63 | 2019 |
| Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults T Picart, M Barritault, D Poncet, LP Berner, C Izquierdo, E Tabouret, ... Neuro-Oncology Advances 3 (1), vdab061, 2021 | 54 | 2021 |
| Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy) J Garcia, J Forestier, E Dusserre, AS Wozny, F Geiguer, P Merle, C Tissot, ... Oncotarget 9 (30), 21122, 2018 | 53 | 2018 |
| O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET) A Lemelin, M Barritault, V Hervieu, L Payen, J Péron, A Couvelard, J Cros, ... Digestive and Liver Disease 51 (4), 595-599, 2019 | 39 | 2019 |
| Characteristics of cerebellar glioblastomas in adults T Picart, M Barritault, J Berthillier, D Meyronet, A Vasiljevic, D Frappaz, ... Journal of neuro-oncology 136, 555-563, 2018 | 36 | 2018 |
| Validity of targeted next-generation sequencing in routine care for identifying clinically relevant molecular profiles in non–small-cell lung cancer: results of a 2-year … A Legras, M Barritault, A Tallet, E Fabre, A Guyard, B Rance, W Digan, ... The Journal of Molecular Diagnostics 20 (4), 550-564, 2018 | 34 | 2018 |
| MEVITEM—A phase I/II trial of vismodegib+ temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation D Frappaz, M Barritault, L Montané, F Laigle-Donadey, O Chinot, ... Neuro-Oncology 23 (11), 1949-1960, 2021 | 27 | 2021 |
| Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors A Brindel, W Althakfi, M Barritault, E Watkin, JM Maury, PP Bringuier, ... Journal of Thoracic Disease 12 (9), 4643, 2020 | 26 | 2020 |
| A unique TGFB1-driven genomic program links astrocytosis, low-grade inflammation and partial demyelination in spinal cord periplaques from progressive multiple sclerosis patients S Nataf, M Barritault, L Pays International journal of molecular sciences 18 (10), 2097, 2017 | 23 | 2017 |
| Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations C Izquierdo, M Barritault, D Poncet, S Cartalat, B Joubert, J Bruna, ... Neurosurgery 85 (3), E448-E456, 2019 | 22 | 2019 |
| Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics C Izquierdo, A Alentorn, A Idbaih, M Simó, G Kaloshi, D Ricard, ... Journal of neuro-oncology 136, 533-539, 2018 | 22 | 2018 |
| Conventional MRI radiomics in patients with suspected early-or pseudo-progression A Bani-Sadr, OF Eker, LP Berner, R Ameli, M Hermier, M Barritault, ... Neuro-Oncology Advances 1 (1), vdz019, 2019 | 21 | 2019 |
| Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma P Serra, A Petat, JM Maury, F Thivolet-Bejui, L Chalabreysse, M Barritault, ... Lung cancer 118, 62-68, 2018 | 19 | 2018 |
| Evaluating targeted next-generation sequencing assays and reference materials for NTRK fusion detection CB Chung, J Lee, M Barritault, PP Bringuier, Z Xu, WY Huang, A Beharry, ... The Journal of Molecular Diagnostics 24 (1), 18-32, 2022 | 18 | 2022 |
| Avoiding new biopsies by identification of IDH1 and TERT promoter mutation in nondiagnostic biopsies from glioma patients M Barritault, T Picart, D Poncet, T Fenouil, A d’Hombres, M Gabut, ... Neurosurgery 87 (4), E513-E519, 2020 | 15 | 2020 |
| Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients A Champagnac, PP Bringuier, M Barritault, S Isaac, E Watkin, F Forest, ... Journal of Thoracic Disease 12 (5), 2172, 2020 | 15 | 2020 |
| An architecture for genomics analysis in a clinical setting using Galaxy and Docker W Digan, H Countouris, M Barritault, D Baudoin, P Laurent-Puig, H Blons, ... GigaScience 6 (11), gix099, 2017 | 14 | 2017 |
François DucrayMD, Department of neuro-oncology, Lyon, FranceDirección de correo verificada de chu-lyon.fr
